Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Geron to Participate at Upcoming Investor Conferences in April


Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences:

A webcast of each fireside chat and corporate presentation will be available through the Investor Relations section of the Company's website under Events. An archive of the webcast will be available on the Company's website for 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class investigational telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. The New Drug Application (NDA) for imetelstat for the treatment of transfusion dependent anemia in patients with lower-risk myelodysplastic syndromes (TD LR-MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs), based on the results from the Phase 3 IMerge clinical trial, is currently under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024. In addition, an MAA is under review in the European Union for the same proposed indication. Furthermore, Geron currently has an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis (R/R MF). To learn more, visit www.geron.com or follow us on LinkedIn.


These press releases may also interest you

at 22:05
LC-Plasma-based Vaccine Research Selected for SCARDA Project
Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and National Institute of Infectious Diseases (NIID) are jointly conducting studies to investigate the protective efficacy of L. lactis strain Plasma [postbiotic] (LC-Plasma) immunization...

at 22:00
NSG BioLabs Fuels Biotech Innovation in Singapore and Southeast Asia Through Partnerships with EnterpriseSG and Merck, Alongside Investments from Celadon Partners and ClavystBio
Since 2019, NSG BioLabs has been a leader in co-working lab spaces in Singapore, and has nurtured over 40 biotech companies, of which the startups have achieved nearly US$400 million funding in total alongside significant business milestonesNSG...

at 21:05
Lifenet Insurance to Improve Employee Work Efficiency
Ivanti Software K.K., the Japanese subsidiary of Ivanti, a tech company that breaks barriers between IT and security departments so that Everywhere Work can thrive, and Lifenet Insurance Co. (Lifenet Insurance), today announced that Ivanti Neurons...

at 21:00
AGON by AOC secures number 1 spot as the world's leading gaming monitor brand
TPV USA, leading display specialist and North America brand license partner for AOC gaming monitors, proudly announces its position as the world's number one gaming monitor brand, per the IDC Quarterly Gaming Tracker report for Q1/2024. AGON by AOC...

at 20:35
INSERTING and REPLACING ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9
Insert as subheadline: NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES The updated release reads: ZYUS LIFE SCIENCES CORPORATION TO PRESENT AT SIDOTI VIRTUAL INVESTOR CONFERENCE MAY 8-9 NOT FOR...

at 20:30
DataShapes AI Taps Kevin Larrabee As Head of Product
DataShapes, Inc., the premier developer of cutting-edge AI solutions targeting the electromagnetic spectrum, announced today that it has named Kevin Larrabee as Head of Product for the company's pioneering AI technology for defense and enterprise...

More news about Science and technology...


News published on and distributed by: